Royalty Pharma (RPRX) Aperçu de l'action
Royalty Pharma plc est un acheteur de redevances biopharmaceutiques et un bailleur de fonds de l'innovation dans l'industrie biopharmaceutique aux États-Unis. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 3/6 |
| Croissance future | 5/6 |
| Performances passées | 2/6 |
| Santé financière | 3/6 |
| Dividendes | 2/6 |
RPRX Community Fair Values
Create NarrativeSee what 50 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Royalty Pharma plc Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$54.50 |
| Plus haut sur 52 semaines | US$54.64 |
| Plus bas sur 52 semaines | US$32.21 |
| Bêta | 0.40 |
| Variation sur 1 mois | 10.37% |
| Variation sur 3 mois | 20.04% |
| Variation sur 1 an | 67.95% |
| Variation sur 3 ans | 68.31% |
| Variation sur 5 ans | 35.84% |
| Évolution depuis l'introduction en bourse | 22.47% |
Nouvelles et mises à jour récentes
Recent updates
Seeking Alpha • May 16
Royalty Pharma: Strong Execution, Expanding Pipeline And More Firepower Ahead
Summary Portfolio Receipts increased 10% to $925 million, while Royalty Receipts grew 13% to $887 million. Q1 confirmed a supportive, broad-based momentum. Management's 2030 Portfolio Receipts target of $4.7 billion increasingly appears conservative. Recent funding agreements with Johnson & Johnson, alongside prior collaborations with Biogen, Merck, and Teva, strengthen Royalty Pharma’s positioning. Capital flexibility and buybacks remain meaningful tailwinds. We remain buyers. Read the full article on Seeking Alpha
Mise à jour du récit • May 02
RPRX: Royalty Deals And Buybacks Will Shape Balanced Forward Outlook
Analysts have raised their blended price target on Royalty Pharma by several dollars to around the mid $40s, citing refined models that factor in slightly higher projected revenue growth, modestly lower profit margins, and continued benefits from recent royalty and financing deals such as the $250m Zymeworks agreement. Analyst Commentary Recent research on Royalty Pharma centers on how the updated price targets line up with the company’s deal pipeline, especially the $250m Zymeworks transaction.
Mise à jour du récit • Apr 17
RPRX: Diversified Royalty Portfolio And Recent Deals Will Support Future Upside
Analysts have nudged their price targets for Royalty Pharma modestly higher, with the average fair value estimate moving from about $59.28 to $60.61. They point to the company's diversified royalty portfolio, favorable deal terms such as the $250m Zymeworks financing, and the broader growth of the biopharma royalty market.Mise à jour du récit • Apr 03
RPRX: Royalty Deals And Dividend Policy Will Shape Balanced Forward Outlook
Analysts have raised the fair value estimate for Royalty Pharma to $46.00 from $40.86, citing updated models that reflect perceived strengths in its biopharma royalty exposure, portfolio diversification, and recent deal activity. Analyst Commentary Recent Street research around Royalty Pharma highlights both constructive and cautious views, giving you a mixed picture of how professionals are thinking about the stock.
Mise à jour du récit • Mar 19
RPRX: Royalty Deals And Buybacks Will Support Future Upside
Analysts have lifted their price target on Royalty Pharma to $51.56 from $51.00, citing updated Street views on its biopharma royalty exposure and recent deal activity as key supports for the revised fair value estimate. Analyst Commentary Recent Street commentary on Royalty Pharma highlights a mix of optimism around its royalty portfolio and business model, alongside some areas where investors may want to stay cautious on execution and deal risk.Mise à jour du récit • Mar 05
RPRX: Royalty Platform And Portfolio Diversification Will Drive Future Upside Potential
Analysts have nudged their targets higher on Royalty Pharma, with the consensus fair value estimate moving from $56.00 to about $59.28. They cite expectations for the company to benefit from growth in the biopharma royalty market, differentiation from competitors, and a more diversified portfolio.Mise à jour du récit • Feb 19
RPRX: Higher P/E Expectations And Buybacks Will Support Future Upside
Analysts have lifted their average price target on Royalty Pharma from about $46 to roughly $51, citing updated assumptions for fair value, discount rate, growth, margins, and a higher future P/E multiple as key drivers behind the move. Analyst Commentary Recent research coverage on Royalty Pharma has centered on refreshed models for fair value and updated assumptions around discount rates, growth, margins, and future P/E multiples.Article d’analyse • Feb 11
Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.235
Royalty Pharma plc's ( NASDAQ:RPRX ) dividend will be increasing from last year's payment of the same period to $0.235...Mise à jour du récit • Feb 05
RPRX: Pending XenoTherapeutics Deal And Dividend Increase Will Shape Near-Term Returns
Analysts have raised their price targets on Royalty Pharma by about $2 to an updated fair value of US$40.86, citing slightly higher long term revenue growth assumptions, a modestly higher future P/E multiple, and largely unchanged discount rate and profit margin inputs. Analyst Commentary Recent research on Royalty Pharma has been mixed, with some firms updating ratings and price targets around the company’s agreed acquisition by XenoTherapeutics at an estimated US$1.82 per share.Article d’analyse • Jan 22
Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's
Royalty Pharma plc's ( NASDAQ:RPRX ) dividend will be increasing from last year's payment of the same period to $0.235...Mise à jour du récit • Jan 21
RPRX: Pending XenoTherapeutics Deal And Hold Downgrade Will Limit Near-Term Upside
Analysts have trimmed their price expectations for Royalty Pharma, citing a revised fair value of $38.00 per share. This reflects updated views on revenue growth, profit margins, and future P/E multiples following the announced acquisition by XenoTherapeutics and the recent downgrade to Hold.Mise à jour du récit • Jan 07
RPRX: Agreed XenoTherapeutics Deal Will Highlight Upside In Royalty Portfolio Earnings Power
Analysts have nudged their fair value target for Royalty Pharma up to US$56.00 from US$55.00. This reflects updated assumptions on slower revenue growth, higher margins and a lower future P/E, while also factoring in the recent downgrade to Hold following the agreed acquisition by XenoTherapeutics at an estimated US$1.82 per share.Mise à jour du récit • Dec 15
RPRX Pending XenoTherapeutics Deal Will Anchor Shares Near Buyout Price
Analysts have nudged their price target on Royalty Pharma up by $1, to $38. This reflects modestly stronger revenue growth assumptions, offset by a slightly higher discount rate and lower projected profit margins, and incorporates the limited upside they see given the pending acquisition by XenoTherapeutics.Mise à jour du récit • Dec 01
RPRX: Share Buybacks Will Drive Value Upon Acquisition Completion
Analysts have revised Royalty Pharma's price target slightly upward from $45.54 to $45.98. They note that the pending acquisition by XenoTherapeutics has reduced uncertainty around the company’s valuation.Mise à jour du récit • Nov 17
RPRX: Share Buybacks And Acquisition Will Drive Outperformance After Downgrade
Analysts have raised Royalty Pharma's price target from $44.10 to $45.54, reflecting updated expectations for revenue growth. However, profit margins are anticipated to decrease following recent acquisition developments.Mise à jour du récit • Nov 02
RPRX: Upcoming Licensing Deals And Share Buybacks Will Drive Long-Term Upside
Narrative Update on Royalty Pharma: Analyst Price Target Revision Analysts have lowered their fair value estimate for Royalty Pharma from $44.86 to $44.10 per share. This revision is based on updated modeling of revenue growth and profit margins.Mise à jour du récit • Sep 04
Emerging Therapies And Licensing Will Expand Royalty Opportunities
Analysts maintain a positive outlook for Royalty Pharma, citing resilience amid sector underperformance, limited exposure to policy and macroeconomic risks, and anticipated seasonal strength, with the consensus price target unchanged at $43.27. Analyst Commentary Bullish analysts expect Q2 to be seasonally strong for large biopharma companies, supporting near-term performance.Article d’analyse • Jul 06
Benign Growth For Royalty Pharma plc (NASDAQ:RPRX) Underpins Its Share Price
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 19x, you may...Article d’analyse • May 31
Here's Why We Think Royalty Pharma (NASDAQ:RPRX) Is Well Worth Watching
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Seeking Alpha • Feb 13
Royalty Pharma: Delivering Growth With A Positive Story Ahead
Summary Royalty Pharma's Q4 results show portfolio receipts of $742 million and operating cash flow of $678 million, which demonstrate solid performance. MorphoSys bond redeployment further enhances higher-returning royalty opportunities. The company has a solid balance sheet with $1.4 billion in cash equivalents, which is worth considering. RPRX's valuation remains compelling, with a double-digit total yield (via buyback and dividend). Read the full article on Seeking AlphaSeeking Alpha • Jan 15
Royalty Pharma: Key Strategic Updates To Be Priced In
Summary Key strategic updates include acquiring RP Management LLC, simplifying the corporate structure, reducing costs, and enhancing shareholder alignment. A new $3 billion share repurchase program and a 5% dividend increase highlight strong capital allocation, maintaining financial flexibility and an investment-grade credit rating. The valuation remains compelling, with a 30% upside. Anticipated savings and buybacks suggest further EPS growth, reinforcing our overweight rating. Read the full article on Seeking AlphaSeeking Alpha • Nov 09
Royalty Pharma: Massive Opportunity Ahead
Summary Royalty Pharma's Q3 results met expectations, with a modest 2024 outlook increase, driven by strong portfolio performance and new royalty acquisitions. The CF franchise remains a key cash cow despite challenges, with Vertex's Venza triple development posing potential headwinds. With a compelling valuation, a $1 billion buyback, and a supportive pipeline, Royalty Pharma is a strong buy. Read the full article on Seeking AlphaRendement pour les actionnaires
| RPRX | US Pharmaceuticals | US Marché | |
|---|---|---|---|
| 7D | 4.7% | 5.3% | 1.1% |
| 1Y | 68.0% | 44.3% | 28.7% |
Rendement vs Industrie: RPRX a dépassé le secteur US Pharmaceuticals qui a rapporté 44.3 % au cours de l'année écoulée.
Rendement vs marché: RPRX a dépassé le marché US qui a rapporté 28.7 % au cours de l'année écoulée.
Volatilité des prix
| RPRX volatility | |
|---|---|
| RPRX Average Weekly Movement | 3.0% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Cours de l'action stable: RPRX n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de RPRX ( 3% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1996 | 100 | Pablo Legorreta | www.royaltypharma.com |
Royalty Pharma plc est un acheteur de redevances biopharmaceutiques et un bailleur de fonds de l'innovation dans l'industrie biopharmaceutique aux États-Unis. Son portefeuille comprend des redevances sur environ 35 thérapies commercialisées et 20 produits candidats en phase de développement dans divers domaines thérapeutiques, tels que les maladies rares, l'oncologie, les neurosciences, les maladies infectieuses, l'hématologie et le diabète. La société a conclu une collaboration pour le financement de la recherche et du développement afin de faire progresser le développement de JNJ-4804, un médicament expérimental pour les maladies auto-immunes.
Royalty Pharma plc Résumé des fondamentaux
| RPRX statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$31.38b |
| Bénéfices(TTM) | US$826.29m |
| Recettes(TTM) | US$2.44b |
29.2x
Ratio P/E9.9x
Ratio P/SLe site RPRX est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| RPRX compte de résultat (TTM) | |
|---|---|
| Recettes | US$2.44b |
| Coût des recettes | -US$366.18m |
| Marge brute | US$2.81b |
| Autres dépenses | US$1.98b |
| Les revenus | US$826.29m |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | 1.86 |
| Marge brute | 115.00% |
| Marge bénéficiaire nette | 33.86% |
| Ratio dettes/capitaux propres | 90.1% |
Quelles ont été les performances à long terme de RPRX?
Voir les performances historiques et les comparaisonsDividendes
1.7%
Rendement actuel des dividendes47%
Ratio de distributionLe site RPRX verse-t-il des dividendes fiables ?
Voir RPRX l'historique des dividendes et les indices de référence| Royalty Pharma dates des dividendes | |
|---|---|
| Date ex-dividende | May 15 2026 |
| Date de paiement du dividende | Jun 10 2026 |
| Jours jusqu'au dividende Ex | 11 days |
| Jours jusqu'à la date de paiement du dividende | 15 days |
Le site RPRX verse-t-il des dividendes fiables ?
Voir RPRX l'historique des dividendes et les indices de référenceAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/25 21:01 |
| Cours de l'action en fin de journée | 2026/05/22 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Royalty Pharma plc est couverte par 14 analystes. 5 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Geoffrey Meacham | Citigroup Inc |
| Prem Chulaki | CrispIdea |